Simbrinza, a 1.0 percent brinzolamide and 0.2 percent brimonidine tartrate suspension, has proven to decrease intraocular pressure by 21 to 35 percent.
Alcon’s glaucoma therapy is currently the only fixed-dose combination without a beta blocker to be offered in the U.S.
More Articles on Ophthalmology:
Twin Falls Vision Clinic Expands, Recruits Dr. Kyle Klingler
3 Statistics on Cataract Surgery Procedure Times in ASCs
Bausch + Lomb, Leica Microsystems Make Global Distributing Agreement
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
